SCHEMBL3589004

SCHEMBL3589004

COCC(=O)CNc1ccc(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F10 P00742 13/20 0.52
POLB P06746 1/20 0.48
KLKB1 P03952 4/20 0.41
GAA P10253 1/20 0.38
KDM4C Q9H3R0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580391 0.89 POLB (0.56) F10POLBKLKB1GAAKDM4C
SCHEMBL3582471 0.89 F10 (0.49) F10POLBKLKB1
SCHEMBL3589002 0.83 F10 (0.51) F10POLBKLKB1
SCHEMBL3577876 0.82 F10 (0.58) F10POLBKLKB1
SCHEMBL3577873 0.81 POLB (0.53) F10POLBKLKB1GAAKDM4C
SCHEMBL3580373 0.81 POLB (0.55) F10POLBKLKB1GAA
SCHEMBL3582633 0.81 POLB (0.57) F10POLBKLKB1
SCHEMBL3589241 0.79 POLB (0.52) F10POLBKLKB1GAAKDM4C
SCHEMBL3581950 0.79 POLB (0.57) F10POLBKLKB1
SCHEMBL3582467 0.78 F10 (0.48) F10POLBKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1697318-B1 PROLINYLARYLACETAMIDES MERCK PATENT GMBH (DE) 2008-08-27 EP claimed
US-20070185189-A1 Prolinylarylacetamides MERCK PATENT GMBH (DE) 2007-08-09 US claimed
US-7732481-B2 Prolinylarylacetamides MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-06-08 US disclosed
US-20070185189-A1 Prolinylarylacetamides MERCK PATENT GMBH (DE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185189-A1 Prolinylarylacetamides F12, F11, F2 F10 5/4885POLB 3435/4885KLKB1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.